Complement eliminates microbes, modulates the adaptive immune system and has important roles in clearance of immune complexes and apoptotic cells, inflammation and tissue regeneration 1,2 . Antibody complexes (classical pathway, CP), lectin complexes (lectin pathway, LP) or spontaneous hydrolysis of the soluble complement protein C3 (alternative pathway, AP) initiates a proteolytic cascade that results in the assembly of enzyme complexes (termed C3 convertases) on surfaces local to the activation stimulus.
Complement eliminates microbes, modulates the adaptive immune system and has important roles in clearance of immune complexes and apoptotic cells, inflammation and tissue regeneration 1, 2 . Antibody complexes (classical pathway, CP), lectin complexes (lectin pathway, LP) or spontaneous hydrolysis of the soluble complement protein C3 (alternative pathway, AP) initiates a proteolytic cascade that results in the assembly of enzyme complexes (termed C3 convertases) on surfaces local to the activation stimulus.
The C3 convertases consist of either one molecule of complement C3b and the serine protease Bb (the so-called C3bBb convertase, generated by AP), or one molecule of C4b and the serine protease C2a (the so-called C4bC2a convertase, generated by CP and LP). C3 convertases cleave soluble, circulating C3, thus leading to the formation of membrane-targeted C3b (ref. 3 ) and release of the anaphylatoxin C3a fragment 4 . Membrane-bound C3b further assembles into C3bBb, which amplifies the activation signal. C3b and its proteolytic fragments trigger phagocytosis and modulate adaptive immune responses via B-cell stimulation 2 . Additional molecules of C3b (termed C3b′ hereafter) have been proposed to associate with the C3 convertases and to form C5 convertases (either C3bBbC3b′ or C4bC2aC3b′) when levels of complement activation are high [5] [6] [7] [8] [9] . This association modulates the activity of the enzyme, causing it to preferentially cleave complement component C5 rather than C3, thereby generating C5b as well as the anaphylatoxin C5a, which potently attracts and activates neutrophils, monocytes and mast cells 10 . C5b assembles with downstream complement components, thus generating the membrane attack complex (MAC), which represents the pore-forming part of the system responsible for lysing Gram-negative bacteria or inducing tissue inflammation 11 . To date, the proposed C5 convertase complexes have proven refractory to purification.
When regulation of complement fails, the system can turn its destructive capabilities against self and can be involved in inflammation, autoimmunity and tissue damage associated with infectious diseases 12, 13 . The US Food and Drug Administration's approval of administration of an activation-blocking antibody against C5 (eculizumab) for patients suffering from paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome demonstrates the therapeutic utility of blocking the pathway at this point. Inhibition at the level of C5 prevents the formation of proinflammatory C5a and MAC but allows for generation of the anaphylotoxin C3a and cellular opsonization by C4b and C3b 10, 14 .
Eculizumab is one of the most expensive drugs in the world, costing approximately $500,000 per patient per year (https://www.nice.org. uk/news/press-and-media/nice-draft-guidance-recommends-eculizumab-soliris-for-treating-very-rare-life-threatening-blood-disorder). There is therefore much interest in the development of new C5-targeted therapeutics including a molecule derived from tick saliva (OmCI; coversin), whose recombinant form is currently undergoing clinical trials 15 . However, a paucity of information about where eculizumab, OmCI and related drugs bind C5, as well as a lack of structural insight into the mechanisms underlying inhibition, has limited further clinical development. Production of new C5 inhibitors and structures of C5-inhibitor complexes may therefore lead to development of improved therapies for diseases driven by complement.
We therefore set out to discover new C5 inhibitors and to determine structures of inhibited C5. In this study, we identified and characterized a new protein family of ~8-kDa tick-derived C5 inhibitors, termed the Rhipicephalus appendiculatus C5 inhibitor (RaCI) family. We present structures that reveal a previously unknown, small RaCI family protein fold. We determined a series of three structures of ternary complexes of C5 with two bound inhibitors (OmCI plus three sequence-diverse members of the RaCI family). Additionally, we found that eculizumab binds at an additional unique site and thus were able to assemble and characterize the structure of a C5-OmCI-RaCI-eculizumab Fab fragment quaternarycomplex. Our structures reveal that all three classes of inhibitors have distinct binding sites spanning multiple C5 domains. In addition, we designed a competition assay whose results conflicted with previously proposed steric models for inhibition by OmCI and eculizumab. Revisiting the early C5 convertase literature in the context of our new data led us to propose that the C5 convertase components assemble around C5 rather than existing as a preassembled entity anchored to the cell surface.
RESULTS

A new family of C5 inhibitors
We found that complete salivary-gland extract from the hard tick R. appendiculatus was able to prevent complement-mediated hemolysis (Supplementary Fig. 1a) . The total protein composition of the complete extract was complex; therefore, to identify the component responsible for the complement-inhibitory activity, we sequentially fractionated the salivary-gland extracts through anion-exchange, reversed-phase and size-exclusion Figure 1 Complement inhibition by RaCI. (a) Sequence alignment of RaCI family members. RaCI1 was purified from salivary-gland extract from R. appendiculatus. RaCI5 is a homolog from the R. appendiculatus transcriptome described in this study. RaCI2, fusion of the partial sequences in GenBank GO496246 and GO496255, Rhipicephalus microplus; RaCI3, GenBank EG364159, Dermacentor andersoni; RaCI4, GenBank GR908966, Hyalomma marginatum; RaCI6, GenBank EG363232, D. andersoni; RaCI7, GenBank EG363717, D. andersoni. Bold, residues conserved in five or more RaCIs; red, residues conserved in all RaCIs; asterisks, conserved cysteines; arrows, truncations used in Figure 4d . A r t i c l e s npg A r t i c l e s chromatography. At each stage, we tested the chromatographiccolumn fractions for complement-inhibitory activity, and we further fractionated fractions with the desired activity. This procedure eventually generated a fraction highly enriched for inhibition of complement, as compared with the total extract; we subjected this fraction to LC-MS/MS and used expressed-sequence-tag databases to identify peptides 16 . However, this search identified no likely candidate genes. We therefore generated a transcriptome from mRNA from salivary-gland extracts, by using RNA sequencing. Reanalysis of the LC-MS/MS data against our new transcriptome identified a single candidate gene in the enriched fraction that, when overexpressed in insect cells, showed complement-inhibiting activity. We named this protein R. appendiculatus complement inhibitor 1 (RaCI1). This ~8-kDa protein bears no sequence similarity to the previously characterized tick complement inhibitor OmCI (~17 kDa). BLAST searches revealed a second RaCI homolog in our R. appendiculatus transcriptome and five additional homologs in other tick species (hereafter termed RaCI2-7) (Fig. 1a) . All RaCI1-7 sequences contained six conserved cysteine residues but displayed low overall sequence conservation (19% identity at the protein level; Supplementary Table 1) . Supernatants from insect cell lines expressing each of these homologs tested positive for complement inhibition (Supplementary Fig. 1b) , thus demonstrating that RaCI1-7 share a common function.
We next measured the activity of one of the homologs (RaCI2) on each of the three major complement-activation pathways, using an ELISA-based assay (Wieslab). We tested RaCI homologs for their ability to inhibit all three complement-activation pathways (Fig. 1b and  Supplementary Fig. 1c ). All had half-maximal inhibitory concentration (IC 50 ) values similar to those previously characterized for the unrelated tick complement inhibitor OmCI. To test whether the RaCI family members act upstream or downstream of cleavage of C3, we assessed whether the anaphylatoxins C3a and C5a were formed for each of the three pathways. Our experiments revealed that RaCIs left C3a levels unaltered but completely abolished formation of C5a in all three pathways (Fig. 1c) . We performed a pulldown assay from blood serum to identify the target of RaCI. The results revealed a single protein specifically bound to RaCI. Western blotting with anti-C5 antibodies confirmed that this protein was C5 (Fig. 1d) . RaCI thus targets complement after the convergence of the three pathways. The higher IC 50 in the AP assay was explained by the higher concentration of C5 present (5.6% serum in the AP assay versus 1% serum in CP and LP pathway assays) rather than by any difference in the ability of RaCIs to inhibit the different 
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A r t i c l e s pathways. The calculated IC 50 values correlated with the concentration of C5 in the assay and reflected an ~1:1 molar ratio of inhibitor to C5. OmCI has been shown to inhibit complement from many different mammalian species 17, 18 ; therefore, we also tested cross-species reactivity for RaCI. RaCI potently inhibited complement from guinea pigs but not from pigs, rats, mice or rabbits. In contrast, as expected on the basis of previous reports 17, 18 , OmCI inhibited complement from all these species ( Fig. 1e and Supplementary Fig. 1d ). These results suggest that the OmCI-binding site on C5 is more highly conserved across species than that targeted by the RaCI family. Together, these data demonstrate that members of our newly identified RaCI family bind human C5 and block the generation of C5a and MAC, thus leaving the upstream part of the complement cascade intact.
Crystal structures of C5-inhibitor complexes
The difference in the ability of RaCI and OmCI to inhibit complement across different species, and the lack of sequence similarity between the two inhibitors, led us to hypothesize that RaCI and OmCI bind different sites on C5. To purify C5-inhibitor complexes, we first used histidine-tagged OmCI to isolate C5 from blood serum ( Fig. 1f and Online Methods). Size-exclusion chromatography and multiangle light scattering (SEC-MALS) data demonstrated that C5 and OmCI bound with a 1:1 molar ratio (Fig. 1g) , a result in agreement with previous data 19 . Adding an excess of free RaCI to the binary complex (and further purification) increased the mass of the complex by ~10 kDa, corresponding to incorporation of one copy of RaCI. The formation of a ternary C5-OmCI-RaCI complex demonstrated that RaCI and OmCI bind different epitopes on C5 (Fig. 1f,g ).
To gain further insight into the mechanism of inhibition of C5 cleavage and activation, we sought to determine whether the antibody drug eculizumab binds an epitope on C5 distinct from those bound by the tick inhibitors. We generated a custom-made active Fab fragment from the patented sequence for eculizumab (hereafter termed EcuFab; Supplementary Fig. 2 ) and added it to the ternary C5-OmCI-RaCI complex ( Fig. 2 ). This addition resulted in the formation of an ~50 kDa-heavier quaternary complex containing C5-OmCI-RaCIEcuFab in a 1:1:1:1 ratio, thus demonstrating that all three inhibitors target different binding sites on C5.
We undertook crystallization studies to gain further insight into the molecular architecture of the inhibited C5 complexes. We produced crystals for the ternary C5-OmCI-RaCI3 complex that diffracted to 2.6 Å ( Table 1 and Fig. 2a ) and solved the structure by molecular replacement, using the existing coordinates for C5 and OmCI. Phases calculated from this partial model clearly revealed density for the RaCI3 component, which we built de novo. RaCI3 is wedged between the MG1, MG2 and C5d domains, whereas OmCI binds a distinct surface of the C5d and CUB domains (described below).
Given the low sequence conservation within the RaCI family, we asked whether all members bind C5 in a similar fashion. Crystallographic structures of C5-OmCI complexes in the presence of RaCI1 and RaCI2 at resolutions of 3.1 Å and 3.0 Å, respectively, provided the answer (Fig. 2b,c) . All three RaCI sequences bound c d The peptide that forms the anaphylatoxin after cleavage by Bb is colored in each picture, and the location of the Cα of Arg751 that forms the C terminus after cleavage is highlighted as a sphere. (e-h) Views of C5 (e), C5-CVF (f), C5-OmCI-RaCI3 (g) and isolated C5a (h) are rotated 180 degrees from the views in a-c, respectively, and essentially are views from within the body of C5. Only the residues that will form the anaphylatoxin and an additional ten amino acids C-terminal to the cleavage site (gray) are shown. The cleavage site, which adopts an extended conformation after an unstructured loop in the C5 and C5-CVF structures 19, 20 , is now in the middle of a helix and is completely buried between helices 1 and 4 of the C5a domain and MG3. 
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A r t i c l e s the same site on C5. The overall domain arrangement of C5 is the same as that of the previously reported C5 structures 19 , and the C345c domain adopts a C3-like orientation, as in the CVF-bound C5 structure 20 ( Supplementary Figs. 3 and 4) . The C345c domain has been observed to adopt multiple orientations relative to the main body of C5 in previous crystallographic structures, and smallangle X-ray scattering data have suggested that the C345c domain is mobile [19] [20] [21] . Accordingly, the atomic B factors suggested different levels of structural order of C345c within our structures. Notably, the other regions showing the greatest variability relative to previous structures were in the C5a and neighboring MG3 domains (Fig. 3) .
In particular, the C terminus of the anaphylatoxin, which has previously been observed 19, 20 in an extended conformation following an unstructured loop, is now completely modeled and adopts a helical conformation, as seen in the NMR structure of human C5a (PDB 1KJS 22 ). This conformation places the Bb-cleavage site (Arg751) in the middle of a helix 36 Å distant from the location of the Bb active site proposed on the basis of earlier models of the C5 convertase interaction 20 . Furthermore, the cleavage site is completely buried between helices 1 and 4 of the C5a domain and the MG3 domain, thus indicating that substantial rearrangement would be required for proteolysis to occur.
The RaCI-C5 interface RaCI binds within the cleft created between the MG1, MG2 and C5d domains ( Fig. 2 and Supplementary Figs. 5 and 6 ). Only the central ~50 amino acids of the RaCI molecules adopted an ordered fold and were observed in the crystallographic density. The three RaCI molecules are identically folded, consisting of two main loops tied together at the base by three conserved disulfide bridges (Fig. 4a) . The fold is unique to the RaCI family because we were not able to identify any close structural homologs in the Protein Data Bank, although the fold is somewhat reminiscent of the disulfiderich structure of small toxins from snake venom 23 . Three stretches of poorly conserved amino acids make extensive contacts with C5 ( Fig. 4c) , and a number of RaCI-C5 interactions are driven by main chain atoms from RaCI. Extensive use of backbone interactions and a conserved overall fold allow for a high sequence divergence among the RaCI homologs (Fig. 4c) .
The relative lack of a canonical hydrophobic core led us to speculate that the RaCI fold might be inherently flexible. To understand any conformational changes that RaCIs might undergo upon C5 binding, we solved the solution structure of apo-RaCI2 by using NMR spectroscopy ( Fig. 4b and Table 2 ). The overlay of the top ten ensemble structures for the apo-RaCI2 revealed the same two ordered loops observed in the structure in the context of the C5-RaCI2 complex.
However, in the C5-bound structure, the tip of loop 1 is bent, and loop 2 is twisted in comparison to its position in the apo structure (Fig. 4b) , thus suggesting that these loops change conformation upon binding of RaCI2 to C5. These regions also exhibit higher intrinsic mobility (as assessed by residual dipolar coupling measurements) for residues that change orientation upon binding (data not shown). As seen in the C5 complex, the N and C termini of RaCI2 are also Lower case, residues not seen in the electron density; red, residues that make van der Waals interactions; bold, hydrogen bonds; italics, salt bridges; brackets, conserved disulfides.
(d) ELISA-based activation assay (CP, classical pathway; AP, alternative pathway) testing inhibitory effects of RaCI2 mutants that lack N and C termini (lacking 10 and 18 amino acids respectively; truncation sites in Fig. 1a) . Error bars, s.e.m. (n = 3 technical replicates). (Fig. 4b) . We made truncated mutants of RaCI2 to assess whether these poorly conserved and flexible residues are required for inhibition and tested the ability of the mutants to inhibit both the CP and AP (Fig. 4d) . Both mutants retained activity with similar potency to that of the full-length protein, thus demonstrating that it is the core of RaCI that is required for inhibition of C5 cleavage and activation.
The OmCI-C5 interface In our crystal structures, OmCI makes contacts with the C5d, CUB and C345c domains of C5 ( Fig. 2d and Supplementary Figs. 7  and 8 ). Seven amino acids near the βC-βD loop and at the C terminus of OmCI make three hydrogen bonds and van der Waals interactions with residues Thr952-Glu958 in the CUB domain. The interactions with the C5d domain are more extensive and include two salt bridges and up to 11 hydrogen bonds. Four discontinuous patches in the OmCI sequence interact with residues between Lys1213 and Asn1241 of the C5d domain. Most contacts occur in the βH-α3 region, which has previously been demonstrated to be critical for binding to C5 (ref. 24) . As in the earlier structures of C5 (refs. 19,20) , portions of the C345c domain are still relatively disordered, but a single amino acid from this domain (Phe1631) forms a point of contact with OmCI residues 62 and 63. OmCI is a bifunctional protein that simultaneously binds C5 and the LTB4 leukotriene 25 . Our structures demonstrate the feasibility of simultaneous C5 and LTB4 binding by OmCI ( Supplementary  Fig. 9 ). The distinct binding sites are located in opposite faces of OmCI, and the LTB4-binding pocket is accessible in the C5-OmCI complex. As seen in earlier structures of OmCI 25, 26 , density within the barrel in our structure suggested that the C5-bound OmCI pocket is occupied, although the weak density suggested a mixed population or partial occupancy, and we were therefore unable to build an atomic model.
Structure of the C5-OmCI-RaCI-EcuFab complex
It is not known where eculizumab binds C5. Data from human subjects have suggested that Arg885 is positioned in or near the epitope, because R885H or R885C polymorphisms induce drug resistance 27, 28 . Antibody-peptide studies have also implicated three short peptides as potentially being involved, although these data are hard to interpret because two of the peptides identified are buried in the folded structure, and the three regions are structurally discontinuous, separated by distances far too large to be incorporated in a single antibody epitope (https://www.google.com/patents/US6355245). We therefore sought to solve the structure of the C5-OmCI-RaCI-EcuFab complex. Our attempts to obtain crystals failed. We therefore turned to transmission electron microscopy (TEM) and single-particle analysis 29 . We acquired 5,587 projection images of different views of the C5-OmCI-RaCI-EcuFab complex preserved in negative stain and calculated an ab initio 3D reconstruction without using the X-ray model as a search reference at any point in the analysis. Fitting of the C5-OmCI-RaCI complex structures into the low-resolution EM envelope produced a good fit and revealed additional density due to the presence of bound EcuFab. We determined the fit of the 
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A r t i c l e s C5 complex to the 3D reconstruction and compared the referencefree class averages with projections of a 16-Å-resolution EM density map, simulated from the X-ray structure (Fig. 5) . The agreement between the projections of the X-ray model and the class averages was excellent and showed additional density due to EcuFab binding the interface between the two lobes of the bipartite C5 structure in two side views (Fig. 5a,b) . The reference-free class averages for similar projection directions indicated moderate flexibility in the positioning of EcuFab relative to the C5 core (Fig. 5c,d) ; this flexibility may explain why the EcuFab density was of slightly lower resolution than the remaining EM density. The EcuFab epitope is centered on the C5 MG7 domain, and both Arg885 and the only surface-exposed peptide previously implicated in forming part of the epitope (Lys879-Cys-883) lie within the binding site (Fig. 5e) .
Inhibition of the C5 convertases
The mechanism of conversion of C5 to C5a and C5b by the C5 convertases C3bBbC3b′ and C4bC2aC3b′ is poorly understood, partly because of their very short half-life. Current structural models are based on the highly stable and presumably analogous cobra venom factor (CVF)-Bb complex (CVFBb; CVF is homologous to C3b), which acts in solution without requiring a second C3b′ molecule. Current models for the C5 convertase are based on structures of C3b, C4b, C5, C5-CVF, CVFB and C3bBb 19, 20, [30] [31] [32] [33] , and they suggest that the MG4, MG5 and MG7 domains of C5 bind the Bb-bound C3b molecule, positioning the active site of the catalytic Bb subunit in the vicinity of the scissile Arg751-Leu752 bond. Neither OmCI nor RaCI binds near the C5a domain or near the proposed C5 convertase-binding site. Thus, inhibition by direct steric hindrance of convertase binding can be ruled out, yet both potently inhibit endogenous convertase-mediated activation of C5 (Fig. 1b and  Supplementary Fig. 1c) . We tested whether OmCI, RaCI and EcuFab could inhibit CVFBb convertase activity (Fig. 6a) . Both RaCI and EcuFab inhibited cleavage by the CVFBb convertase, whereas, as previously reported 15 , OmCI did not block CVFBb activity (Fig. 6a) .
The difference in the ability of the three inhibitors to interfere with a CVF-based convertase contrasts strongly with their equal abilities to inhibit the native C3bBbC3b′ and C4bC2aC3b′ convertases ( Supplementary Figs. 1 and 2 and Fig. 1b) .
Next, we designed a competition experiment in which highly purified inhibited complexes were added to an ELISA-based CP assay. All binary and ternary complexes of C5 and the tick inhibitors competed with native C5, thus demonstrating that these complexes still bind the C5 convertase ( Fig. 6b and Supplementary  Fig. 10 ). Unlike RaCI and OmCI, the monoclonal antibody eculizumab has been suggested to act sterically by preventing C5 convertase 28 , a binding mode now confirmed by our EM data (Supplementary Fig. 11) . Complexes of C5 with EcuFab bound (C5-OmCI-RaCI-EcuFab, Fig. 6b ; C5-EcuFab, Supplementary Fig. 10 ) also inhibited MAC formation in the competition assay, thus suggesting that, unexpectedly, EcuFab does not prevent binding of the inhibited C5 complex to the convertase. Together, our results demonstrate that C5-CVF interactions do not provide a suitable model for interactions between C5 and the endogenous C5 convertases.
DISCUSSION
We demonstrated how three clinically important proteins 34 target C5, revealing why patients carrying an R885H or R885C polymorphism cannot be treated with eculizumab 27 and how OmCI binds LTB4 and C5 simultaneously. Additionally, we identified a new family of C5 inhibitors containing highly divergent sequences that nevertheless adopt a conserved fold targeting the same site on C5. Unlike the human-specific eculizumab, RaCI exhibits cross-species reactivity, thus potentially enabling study of therapeutic efficacy in animal models of disease. All three inhibitor classes are similarly potent complement inhibitors in vitro, but RaCI (~8 kDa) is half the size of OmCI (~17 kDa) and is much smaller than eculizumab (~150 kDa). We showed that the size of RaCI may be further reduced (to ~5 kDa) by removal of the flexible N and C termini, to aid in drug administration. The nonrelated tick proteins OmCI and RaCI target different sites on C5 (C5d-CUB and C5d-MG1-MG2, respectively), and both sites are distinct from that bound by eculizumab. All three inhibitor-binding sites are distant from the site of cleavage of C5 by the convertase. Preliminary data have already demonstrated that OmCI may provide an efficient therapeutic alternative for patients carrying polymorphisms in the eculizumab-binding site (http://ash. confex.com/ash/2015/webprogram/Paper79479.html), and it is likely that the RaCI family members will prove equally potent.
It is reasonably well understood how C3 convertases cleave C3, but the mechanism of the analogous C5 convertases remains elusive. C5 cleavage requires both the C3 convertase (C4bC2a or C3bBb) and an additional surface-bound molecule of C3b′ generated by the C3 convertase [6] [7] [8] [9] 35 . C5 is presumed to bind the endogenous convertase in a manner similar to its binding of CVF 20 , even though the CVF convertase is not dependent on additional C3b′ or surfaces. The exact role of the C3b′ molecule in the C5 convertase activity is disputed. Some studies have shown that C3b′ can covalently attach through its C3d domain to C4b or C3b in the C3 convertase, thus suggesting that the resulting ternary complexes bind and cleave C5 (refs. 36,37), although it has recently been shown that this attachment is not required for cleavage 38 . On the basis of crystal structures of C3bBb, C5-CVF and C4b 20, 31, 32 , the reaction of C3b′ with the C3 convertase has been proposed to induce a conformational change in the convertase moiety that leads to a substrate preference for C5; C5 binding is presumed to occur on the opposite edge of the C3 convertase, in a manner analogous to the binding of C5 to CVF, thus positioning the Bb or C2a protease near the cleavage site (Fig. 7a and ref. 31) .
However, our competition assays showed that EcuFab-bound complexes still inhibit conversion of C5 despite our structural evidence that EcuFab-bound C5 would be unable to interact with the convertase in the mode implied by the C5-CVF-based convertase models. Hence, a distinct interaction event, using a surface different from the EcuFab-binding site, must occur before any C5-CVF-like mode of convertase interaction. This scenario is consistent with an earlier model for the endogenous C5 convertase, in which C5 has been proposed to directly bind C3b′ (coupled to the surface through its thioester), possibly concomitantly with a conformational change that enables cleavage by soluble or surface-bound C3 convertase 35 . This model would also explain why a high density of C3b′ coupled to the surface is required for cleavage by the endogenous convertase 7, 38 : two distinct C5 interaction events on the surface would be required (Fig. 7b) . Whether C5 remains bound to C3b′ while simultaneously binding the C3 convertase or whether a molecule of C5 with a shortlived altered conformation transfers to a C3 convertase remains to be investigated. Both scenarios would explain why high densities of surface-coupled C3b′ are required.
In addition to lacking a requirement for C3b′ and surfaces, the CVFconvertase clearly differs from the endogenous convertase because OmCI, the Staphylococcus aureus inhibitor SSL7 and point mutations in the C345c domain of C5 all inhibit endogenous C5 convertases but not CVF-based convertases (this study and refs. 15, 38) . Our new model proposes that cleavage of C5 by endogenous convertases requires two distinct interactions at the surface (Fig. 7b) . Presumably CVFconvertases do not require the priming interaction to promote productive interactions with the enzyme, perhaps because of higher-affinity C5 binding by CVF 39 . Our structures suggest that EcuFab sterically prevents interactions with CVF but that RaCI does not act in the same way ( Supplementary Fig. 11 ). Instead, binding of RaCI may lock C5 into a conformation that cannot interact with either the CVF convertases or the C3 convertase component of the endogenous pathway. Alternatively, because the C5a scissile bond in our doubly inhibited C5 (Fig. 3c,f) is inaccessible for cleavage by Bb, RaCI may act by preventing a structural 'priming' event that rearranges this region to a conformation more similar to that in the C5-CVF complex (Fig. 3b,e and ref. 20) . It is harder to propose mechanisms for inhibitors and mutations that differentially affect endogenous and CVF convertases. However, similarly to the RaCI mechanism, these inhibitors may lock C5 in a conformation that cannot interact with the endogenous C3 convertase, although this lock may be too weak to prevent interactions with the more tightly binding CVF convertase 39 . Although the nature of the priming event in the endogenous convertase activity remains unknown, the single point of contact of OmCI with the C345c domain of C5 involves a residue (Phe1631) that, when mutated, reduces the ability of the endogenous convertase but not the CVF convertase to cleave C5 (ref. 40) . This result suggests that the priming event may involve rearrangements of the highly mobile C345c domain.
In conclusion, our study suggests that the C5 convertase is not a preassembled complex. Our data provide strong support for a model in which substantial conformational changes in C5 take place after binding to surface-bound C3b′, thus priming C5 for cleavage by the bona fide C3 convertases. The wide variety of inhibitor structures and binding sites on C5 revealed here suggest that inhibition of this stage of complement activation may be achieved via many mechanistically distinct inhibition strategies, thus potentially allowing for fine-tuning of therapeutic effects.
METHODS
Methods and any associated references are available in the online version of the paper. Approximately 300 glands from male ticks were resuspended in PBS and homogenized in a 1-ml Dounce homogenizer (Fisher Scientific). Cleared extract was dialyzed against 25 mM NaPi, pH 7.0, and loaded onto a MonoQ 5/50 HR column (GE). The pH of the flow through was set to ~1 with 1 M HCl, and proteins were fractionated on a Dynamax 300-Å C8 column (Rainin) with 0.1% trifluoroacetic acid (buffer A) and 80% acetonitrile and 0.1% trifluoroacetic acid (buffer B). A gradient of 5-80% buffer B over 20 column volumes (CV) was used. Collected fractions were freeze-dried and resuspended in PBS. Fractions that inhibited complement were pooled and separated on a TSKgel G3000 SW xl column (Tosoh Bioscience) with PBS as a running buffer. The fractions were monitored for activity, and the most active fraction was selected for in-solution trypsin digestion and LC-MS-MS analysis.
Transcriptome sequencing and assembly. Fifty salivary glands from male and female ticks were each dissolved in 1 ml TRIzol (Ambion). 100 µl of 1-bromo-3-chloropropane was added, and each sample was vigorously mixed. After centrifugation at 12,000g for 15 min at 4 °C, the colorless upper phase containing the RNA was transferred to a fresh tube, after which an equal volume of 70% ethanol was added, and the sample was vortexed. Total RNA was extracted with a PureLink RNA Mini Kit (Ambion), per the manufacturer's protocol. RNA was eluted in 30 µl RNase-free water, and the quality of the RNA was assessed on a Bioanalyzer (Bio-Rad). The mRNA fraction was selected from approximately 6 µg of total RNA with poly(T) beads before conversion to cDNA. Second-strand cDNA synthesis incorporated dUTP. The cDNA was end-repaired, A-tailed and adaptor-ligated. Different adapters were used for RNA from male and female ticks. Before amplification, samples were subjected to uridine digestion. Mixed female and male samples were 100-bp paired-end sequenced in two lanes on a HiSeq sequencer (Illumina). Sequences were assembled de novo with the Trinity package with default settings 41 , thus resulting in 118,614 female and 81,358 malespecific transcripts. From these, six translation frames were generated, which were used as a database for LC-MS-MS analysis of purified salivary proteins.
Expression and purification of heterologous proteins. His-RaCI and nontagged homologs were expressed in Drosophila melanogaster S2 suspension cells (Expres2ion Biotechnologies). Codon-optimized genes (GeneArt) were cloned into pExpreS2-2 vectors including a BiP signal peptide or native signal peptide (Supplementary Table 2 ). Transfections to obtain stable cell lines were carried out per the manufacturer's instructions, and 8 d after transfection the spent medium was tested for complement-inhibiting activity.
RaCI family members expressed in insect cells were glycosylated, and therefore we expressed RaCI1-4 in Escherichia coli Shuffle T7 cells (New England BioLabs). Codon-optimized genes without the signal peptide were cloned into pETM14 vectors (European Molecular Biology Laboratory) with NcoI or BspHI and NotI restriction sites to yield 3C-cleavable histidine-tagged proteins (Supplementary Table 2 ). Cells were grown until an OD 600 nm of 0.6-0.8 was reached and were then induced with 0.5 mM IPTG and further incubated at 21 °C for 16 h. Cells were lysed in 150 mM NaCl and 50 mM NaPi, pH 8.0, and proteins were purified on HisTrap HP columns (GE). Histidine tags were removed with HRV 3C protease, and proteins were subsequently purified by a reverse HisTrap-column step. RaCIs were subsequently dialyzed against 2 mM cystine, 1 mM cysteine, and 20 mM ethanolamine, pH 9.0, twice for 24-28 h at 4 °C to aid in disulfide formation. RaCI1-3 were then purified on a MonoQ GL column (GE) with 20 mM ethanolamine, pH 9.0, and a gradient of NaCl (RaCI1, 0-100 mM; RaCI2, 50-350 mM; and RaCI3, 0-250 mM). RaCI4 was purified on a MonoS GL column (GE) with 20 mM MES, pH 5.5, with a 0-250 mM NaCl gradient. Protein was dialyzed against PBS and frozen until further use. Truncated RaCI2 variants used in Figure 4d (Supplementary Table 2) were produced similarly as wild type, but cysteine/cystine dialysis was followed by purification with a Superdex 75 10/30 column (GE) with PBS as running buffer.
Histidine-tagged OmCI carrying two glycosylation mutations (N78Q and N102Q) (Supplementary Table 2 ) was expressed with a Kluyveromyces lactis Protein Expression Kit (New England BioLabs), per the manufacturer's instructions. The vector was linearized with SacII before transformation. Expression was performed in 10 g/L yeast extract and 20 g/L peptone supplemented with 2% galactose. After 3 or 4 d of expression, spent medium was filtered and loaded onto a cOmplete His-Tag Purification Column (Roche); this was followed by a wash and elution step with PBS supplemented with 250 mM imidazole. Eluted OmCI was loaded on a Superdex 75 16/60 column (GE), and peak fractions were pooled, dialyzed and frozen until further use.
Purification of C5 complexes. Outdated human serum was used for preparation of C5 complexes for crystallization, MALS and some of the competition assays. Serum was thawed and cleared by centrifugation and filtration. 4 mg histidine-tagged OmCI was incubated with 200 ml serum at room temperature for 30 min. C5-OmCI complexes were loaded on 2 × 5 ml Ni-NTA columns (Qiagen). Columns were washed with 30 CV PBS and 20 mM imidazole, and this was followed by elution with 3 CV PBS and 250 mM imidazole. After being dialyzed against PBS, the complexes were further purified on a MonoQ 10/100 GL column (GE) with a 0-35% gradient of PBS (buffer A) and PBS and 1 M NaCl (buffer B) over 30 CV. Fractions containing pure complexes were dialyzed against 100 mM NaCl and 20 mM HEPES, pH 7.5. After dialysis, a five-fold molar excess of RaCI was added, and samples were incubated for 30 min at room temperature and resolved on a Superdex 200 10/30 HR column (GE) with 100 mM NaCl and 20 mM HEPES, pH 7.5. Ternary complexes were used for crystallization.
For competition experiments, pure C5 (Complement Technologies) was incubated with a two-fold molar excess of RaCI, OmCI or EcuFab to create the binary complexes. EcuFab is a custom-made Fab fragment with the manufacturer's framework (Ab00296-10.6, Absolute Antibody) and includes the V L and V H sequences of eculizumab (European Patent Office EP0758904 A1). Excess inhibitor was removed with a Superdex 200 5/50 column (GE) in PBS. For MALS and competition experiments, C5-OmCI complexes purified from serum were incubated with a three-fold molar excess of RaCI3 and EcuFab. Excess inhibitor was removed by gel filtration on a Superdex 200 10/30 HR column (GE) with 100 mM NaCl and 20 mM HEPES, pH 7.5. Peak fractions were dialyzed against PBS.
Hemolysis assay.
Sheep red blood cells (TCS Biosciences) were washed with PBS and sensitized with Anti-Sheep Red Blood Cell Stroma antibody (S1389, Sigma-Aldrich) in 142 mM NaCl, 50 mM sodium 5,5-diethylbarbiturate, 0.1% gelatin, 0.15 mM CaCl 2 , and 0.5 mM MgCl 2 , pH 7.35 (GVB 2+ ). 50 µl cells (5 × 10 8 cells/ml) was mixed with an equal volume of diluted serum in GVB 2+ and incubated at 37 °C for 1 h with shaking. 100 µl of PBS was added, and nonlysed cells were pelleted by centrifugation. 100 µl of the supernatant was transferred to a clean plate, and hemolysis was quantified at A 405 . Cells with GVB 2+ instead of serum were used as a blank, and cells with serum only were used for normalization (100% activity). Mouse hemolysis assays were performed with fresh serum and 1 × 10 8 sensitized cells/ml in the presence of 5% MCAR (Complement Technology). Final serum dilutions used were: 1:80 (human), 1:20 (mouse), 1:40 (rabbit), 1:160 (rat), 1:40 (pig) and 1:640 (guinea pig). Human serum was from healthy volunteers, mouse serum was a kind gift from D.R. Greaves (University of Oxford, UK), pig serum was a kind gift from T.E. Mollnes (Oslo University Hospital, Norway), rat and guinea pig serum were from Complement Technology, and rabbit serum was from Pal Freeze.
Complement ELISA. The effect of RaCI2 on all three pathways was tested with a Wieslab complement system screen (Euro Diagnostica), per the manufacturer's instructions. Measurements were subtracted with buffer only and normalized for serum-only samples (100% activity). Other classical and alternative pathway assays were carried out as previously described 42 , with the following modifications. 2 µg/ml IgM (Bio-Rad) and 1.8 mg/ml LPS from Salmonella typhosa (Sigma-Aldrich) were used to coat ELISA plates. Human serum was diluted 1:100 (classical pathway) or 1:10 (alternative pathway). MAC deposition was detected with primary antibodies against C5b-9 (ab66768 (aE11), Abcam), and secondary anti-mouse IgG HRP conjugate (W4021, Promega). HRP activity was detected with 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) liquid substrate (Sigma-Aldrich), and the reaction was stopped by addition of an equal volume of 1% SDS. The absorption was measured at 405 nm. Measurements were subtracted npg
